Aclaris Therapeutics (ACRS) FCF Margin (2017 - 2026)

Aclaris Therapeutics' FCF Margin history runs 10 years deep, the most recent figure standing at 909.92% for Q1 2026.

• In Q1 2026, FCF Margin fell 958.0% year-over-year to 909.92%; the TTM figure through Mar 2026 stood at 623.83% (down 55439.0% YoY), while the FY2025 annual figure was 602.27%, down 49439.0% from the prior year.
• FCF Margin was 909.92% for Q1 2026 at Aclaris Therapeutics, up from 1008.88% in the prior quarter.
• In the past five years, FCF Margin ranged from a high of 506.21% in Q3 2024 to a low of 1450.79% in Q1 2022.
• Historically, FCF Margin has averaged 595.5% across 5 years, with a median of 563.53% in 2025.
• The sharpest annual moves came in 2022 and 2025: FCF Margin soared 88561 bps in 2022, then sank 91184 bps in 2025.
• A 5-year view of FCF Margin shows it stood at 254.3% in 2022, then soared by 83 bps to 43.79% in 2023, then slumped by 122 bps to 97.04% in 2024, then slumped by 940 bps to 1008.88% in 2025, then increased by 10 bps to 909.92% in 2026.
• The last three FCF Margin figures came in at 909.92% (Q1 2026), 1008.88% (Q4 2025), and 332.07% (Q3 2025), per Business Quant data.